Loading…
N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy
Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/...
Saved in:
Published in: | Journal of pharmacological sciences 2021-12, Vol.147 (4), p.315-324 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3 |
container_end_page | 324 |
container_issue | 4 |
container_start_page | 315 |
container_title | Journal of pharmacological sciences |
container_volume | 147 |
creator | Long, Chun-mei Zheng, Qi-xue Zhou, Yi Liu, Yuan-ting Gong, Liu-ping Zeng, Ying-chun Liu, Sha |
description | Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/PS1 mice mimicking the AD model. NITyr improved motor coordination in the rotarod test (RRT) and ameliorated spatial memory in the Morris water maze (MWM) but did not increase spontaneous locomotor activity in the open field test (OFT). In addition, NITyr protected neurons against β-amyloid (Aβ) injury via hematoxylin-eosin (HE) and Nissl staining. Moreover, the related biochemical indexes showed that NITyr reduced the levels of Aβ40 and Aβ42 in the hippocampus but did not affect the expression of p-APP and β-secretase 1 (BACE1). Furthermore, the autophagy inhibitor 3-methyladenine (3 MA) attenuated the effect of NITyr on animal behaviors and neurons. Meanwhile, NITyr upregulated the expression levels of LC3-II and Beclin-1, which were weakened by AM630 (an antagonist of CB2 receptor and a weak partial agonist of CB1 receptors). AM630 also weakened the role of NITyr in animal behaviors. Thus, NITyr improved behavioral impairment and neural loss by inducing autophagy mainly mediated by the CB2 receptor, and weakly mediated by the CB1 receptor. |
doi_str_mv | 10.1016/j.jphs.2021.08.008 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8f3f3fd379a1485b80c8ab69110d28e9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1347861321000839</els_id><doaj_id>oai_doaj_org_article_8f3f3fd379a1485b80c8ab69110d28e9</doaj_id><sourcerecordid>2583443150</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEoqXwBTggH7kk9dj540hcqqpApQpWAs6WY0-2jrJ2sJ1V99vjZcsekQ8ejd78RvNeUbwHWgGF9nqqpuUxVowyqKioKBUvikvgdVeKthYvzzXwi-JNjBOlTOS518UFr9uWN8Avi6dv5Wydn_Ewp0Pw0Tok-IQhReJwDX4JPqFOdp_b45irSKwjN5vN9eYHkBSUi1t0VpOd1Uj2VhGtnFNDZlpDAmpckg_lDo1VCQ1Ra_LLo9oe3havRjVHfPf8XxW_Pt_9vP1aPnz_cn9781Dquqep1E3ToTIIvW5xoNAjDEorpiiMpqkHYNC10JlaKzN2lDMAUXNosIG2RTbwq-L-xDVeTXIJdqfCQXpl5d-GD1upQrJ6RilGnp_hXa-gFs0gqBZqaHsAapjAPrM-nljZld8rxiR3NmqcZ-XQr1GyRvD6uJ1mKTtJdTY1BhzPq4HKY3pyksf05DE9SYXM6eWhD8_8dciOnUf-xZUFn04CzI7tLQYZtUWns7vZ6pRPsv_j_wHtlK0q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2583443150</pqid></control><display><type>article</type><title>N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy</title><source>ScienceDirect Journals</source><creator>Long, Chun-mei ; Zheng, Qi-xue ; Zhou, Yi ; Liu, Yuan-ting ; Gong, Liu-ping ; Zeng, Ying-chun ; Liu, Sha</creator><creatorcontrib>Long, Chun-mei ; Zheng, Qi-xue ; Zhou, Yi ; Liu, Yuan-ting ; Gong, Liu-ping ; Zeng, Ying-chun ; Liu, Sha</creatorcontrib><description>Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/PS1 mice mimicking the AD model. NITyr improved motor coordination in the rotarod test (RRT) and ameliorated spatial memory in the Morris water maze (MWM) but did not increase spontaneous locomotor activity in the open field test (OFT). In addition, NITyr protected neurons against β-amyloid (Aβ) injury via hematoxylin-eosin (HE) and Nissl staining. Moreover, the related biochemical indexes showed that NITyr reduced the levels of Aβ40 and Aβ42 in the hippocampus but did not affect the expression of p-APP and β-secretase 1 (BACE1). Furthermore, the autophagy inhibitor 3-methyladenine (3 MA) attenuated the effect of NITyr on animal behaviors and neurons. Meanwhile, NITyr upregulated the expression levels of LC3-II and Beclin-1, which were weakened by AM630 (an antagonist of CB2 receptor and a weak partial agonist of CB1 receptors). AM630 also weakened the role of NITyr in animal behaviors. Thus, NITyr improved behavioral impairment and neural loss by inducing autophagy mainly mediated by the CB2 receptor, and weakly mediated by the CB1 receptor.</description><identifier>ISSN: 1347-8613</identifier><identifier>EISSN: 1347-8648</identifier><identifier>DOI: 10.1016/j.jphs.2021.08.008</identifier><identifier>PMID: 34663513</identifier><language>eng</language><publisher>Japan: Elsevier B.V</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - metabolism ; Alzheimer Disease - psychology ; Amyloid beta-Peptides - metabolism ; Amyloid beta-Protein Precursor ; Animals ; APP/PS1 transgenic mice ; Autophagy ; Autophagy - drug effects ; Cannabinoid receptor ; Disease Models, Animal ; Hippocampus - metabolism ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; N-linoleyltyrosine ; Neuroprotection ; Neuroprotective Agents ; Presenilin-1 ; Psychomotor Performance - drug effects ; Receptor, Cannabinoid, CB1 - metabolism ; Receptor, Cannabinoid, CB2 - metabolism ; Receptors, Cannabinoid ; Spatial Memory - drug effects ; Tyrosine - analogs & derivatives ; Tyrosine - pharmacology</subject><ispartof>Journal of pharmacological sciences, 2021-12, Vol.147 (4), p.315-324</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Production and hosting by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3</citedby><cites>FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1347861321000839$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34663513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Long, Chun-mei</creatorcontrib><creatorcontrib>Zheng, Qi-xue</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Liu, Yuan-ting</creatorcontrib><creatorcontrib>Gong, Liu-ping</creatorcontrib><creatorcontrib>Zeng, Ying-chun</creatorcontrib><creatorcontrib>Liu, Sha</creatorcontrib><title>N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy</title><title>Journal of pharmacological sciences</title><addtitle>J Pharmacol Sci</addtitle><description>Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/PS1 mice mimicking the AD model. NITyr improved motor coordination in the rotarod test (RRT) and ameliorated spatial memory in the Morris water maze (MWM) but did not increase spontaneous locomotor activity in the open field test (OFT). In addition, NITyr protected neurons against β-amyloid (Aβ) injury via hematoxylin-eosin (HE) and Nissl staining. Moreover, the related biochemical indexes showed that NITyr reduced the levels of Aβ40 and Aβ42 in the hippocampus but did not affect the expression of p-APP and β-secretase 1 (BACE1). Furthermore, the autophagy inhibitor 3-methyladenine (3 MA) attenuated the effect of NITyr on animal behaviors and neurons. Meanwhile, NITyr upregulated the expression levels of LC3-II and Beclin-1, which were weakened by AM630 (an antagonist of CB2 receptor and a weak partial agonist of CB1 receptors). AM630 also weakened the role of NITyr in animal behaviors. Thus, NITyr improved behavioral impairment and neural loss by inducing autophagy mainly mediated by the CB2 receptor, and weakly mediated by the CB1 receptor.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - psychology</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Amyloid beta-Protein Precursor</subject><subject>Animals</subject><subject>APP/PS1 transgenic mice</subject><subject>Autophagy</subject><subject>Autophagy - drug effects</subject><subject>Cannabinoid receptor</subject><subject>Disease Models, Animal</subject><subject>Hippocampus - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>N-linoleyltyrosine</subject><subject>Neuroprotection</subject><subject>Neuroprotective Agents</subject><subject>Presenilin-1</subject><subject>Psychomotor Performance - drug effects</subject><subject>Receptor, Cannabinoid, CB1 - metabolism</subject><subject>Receptor, Cannabinoid, CB2 - metabolism</subject><subject>Receptors, Cannabinoid</subject><subject>Spatial Memory - drug effects</subject><subject>Tyrosine - analogs & derivatives</subject><subject>Tyrosine - pharmacology</subject><issn>1347-8613</issn><issn>1347-8648</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kU9v1DAQxSMEoqXwBTggH7kk9dj540hcqqpApQpWAs6WY0-2jrJ2sJ1V99vjZcsekQ8ejd78RvNeUbwHWgGF9nqqpuUxVowyqKioKBUvikvgdVeKthYvzzXwi-JNjBOlTOS518UFr9uWN8Avi6dv5Wydn_Ewp0Pw0Tok-IQhReJwDX4JPqFOdp_b45irSKwjN5vN9eYHkBSUi1t0VpOd1Uj2VhGtnFNDZlpDAmpckg_lDo1VCQ1Ra_LLo9oe3havRjVHfPf8XxW_Pt_9vP1aPnz_cn9781Dquqep1E3ToTIIvW5xoNAjDEorpiiMpqkHYNC10JlaKzN2lDMAUXNosIG2RTbwq-L-xDVeTXIJdqfCQXpl5d-GD1upQrJ6RilGnp_hXa-gFs0gqBZqaHsAapjAPrM-nljZld8rxiR3NmqcZ-XQr1GyRvD6uJ1mKTtJdTY1BhzPq4HKY3pyksf05DE9SYXM6eWhD8_8dciOnUf-xZUFn04CzI7tLQYZtUWns7vZ6pRPsv_j_wHtlK0q</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Long, Chun-mei</creator><creator>Zheng, Qi-xue</creator><creator>Zhou, Yi</creator><creator>Liu, Yuan-ting</creator><creator>Gong, Liu-ping</creator><creator>Zeng, Ying-chun</creator><creator>Liu, Sha</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20211201</creationdate><title>N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy</title><author>Long, Chun-mei ; Zheng, Qi-xue ; Zhou, Yi ; Liu, Yuan-ting ; Gong, Liu-ping ; Zeng, Ying-chun ; Liu, Sha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - psychology</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Amyloid beta-Protein Precursor</topic><topic>Animals</topic><topic>APP/PS1 transgenic mice</topic><topic>Autophagy</topic><topic>Autophagy - drug effects</topic><topic>Cannabinoid receptor</topic><topic>Disease Models, Animal</topic><topic>Hippocampus - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>N-linoleyltyrosine</topic><topic>Neuroprotection</topic><topic>Neuroprotective Agents</topic><topic>Presenilin-1</topic><topic>Psychomotor Performance - drug effects</topic><topic>Receptor, Cannabinoid, CB1 - metabolism</topic><topic>Receptor, Cannabinoid, CB2 - metabolism</topic><topic>Receptors, Cannabinoid</topic><topic>Spatial Memory - drug effects</topic><topic>Tyrosine - analogs & derivatives</topic><topic>Tyrosine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Long, Chun-mei</creatorcontrib><creatorcontrib>Zheng, Qi-xue</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Liu, Yuan-ting</creatorcontrib><creatorcontrib>Gong, Liu-ping</creatorcontrib><creatorcontrib>Zeng, Ying-chun</creatorcontrib><creatorcontrib>Liu, Sha</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of pharmacological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Long, Chun-mei</au><au>Zheng, Qi-xue</au><au>Zhou, Yi</au><au>Liu, Yuan-ting</au><au>Gong, Liu-ping</au><au>Zeng, Ying-chun</au><au>Liu, Sha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy</atitle><jtitle>Journal of pharmacological sciences</jtitle><addtitle>J Pharmacol Sci</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>147</volume><issue>4</issue><spage>315</spage><epage>324</epage><pages>315-324</pages><issn>1347-8613</issn><eissn>1347-8648</eissn><abstract>Anandamide (AEA) analogs show fair effects in counteracting the deterioration of Alzheimer's disease (AD). Our previous studies demonstrated that AEA analog-N-linoleyltyrosine (NITyr) exerted significant activities. In our current research, the role and mechanisms of NITyr were assessed in APP/PS1 mice mimicking the AD model. NITyr improved motor coordination in the rotarod test (RRT) and ameliorated spatial memory in the Morris water maze (MWM) but did not increase spontaneous locomotor activity in the open field test (OFT). In addition, NITyr protected neurons against β-amyloid (Aβ) injury via hematoxylin-eosin (HE) and Nissl staining. Moreover, the related biochemical indexes showed that NITyr reduced the levels of Aβ40 and Aβ42 in the hippocampus but did not affect the expression of p-APP and β-secretase 1 (BACE1). Furthermore, the autophagy inhibitor 3-methyladenine (3 MA) attenuated the effect of NITyr on animal behaviors and neurons. Meanwhile, NITyr upregulated the expression levels of LC3-II and Beclin-1, which were weakened by AM630 (an antagonist of CB2 receptor and a weak partial agonist of CB1 receptors). AM630 also weakened the role of NITyr in animal behaviors. Thus, NITyr improved behavioral impairment and neural loss by inducing autophagy mainly mediated by the CB2 receptor, and weakly mediated by the CB1 receptor.</abstract><cop>Japan</cop><pub>Elsevier B.V</pub><pmid>34663513</pmid><doi>10.1016/j.jphs.2021.08.008</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1347-8613 |
ispartof | Journal of pharmacological sciences, 2021-12, Vol.147 (4), p.315-324 |
issn | 1347-8613 1347-8648 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_8f3f3fd379a1485b80c8ab69110d28e9 |
source | ScienceDirect Journals |
subjects | Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer Disease - psychology Amyloid beta-Peptides - metabolism Amyloid beta-Protein Precursor Animals APP/PS1 transgenic mice Autophagy Autophagy - drug effects Cannabinoid receptor Disease Models, Animal Hippocampus - metabolism Mice Mice, Inbred C57BL Mice, Transgenic N-linoleyltyrosine Neuroprotection Neuroprotective Agents Presenilin-1 Psychomotor Performance - drug effects Receptor, Cannabinoid, CB1 - metabolism Receptor, Cannabinoid, CB2 - metabolism Receptors, Cannabinoid Spatial Memory - drug effects Tyrosine - analogs & derivatives Tyrosine - pharmacology |
title | N-linoleyltyrosine exerts neuroprotective effects in APP/PS1 transgenic mice via cannabinoid receptor-mediated autophagy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A29%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=N-linoleyltyrosine%20exerts%20neuroprotective%20effects%20in%20APP/PS1%20transgenic%20mice%20via%20cannabinoid%20receptor-mediated%20autophagy&rft.jtitle=Journal%20of%20pharmacological%20sciences&rft.au=Long,%20Chun-mei&rft.date=2021-12-01&rft.volume=147&rft.issue=4&rft.spage=315&rft.epage=324&rft.pages=315-324&rft.issn=1347-8613&rft.eissn=1347-8648&rft_id=info:doi/10.1016/j.jphs.2021.08.008&rft_dat=%3Cproquest_doaj_%3E2583443150%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c490t-c557eade19c6eb019e1baca2a01fd54b1217617d4cadf70321184315e5166e2b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2583443150&rft_id=info:pmid/34663513&rfr_iscdi=true |